TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02100722

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FFR guided PCI
Study: NCT01916226

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FPNS
Description: Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: FPNS Placebo
Description: Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetirizine
Description: Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cetirizine Placebo
Description: Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
Study: NCT03295786

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebral Dopamine Neurotrophic Factor
Description: Repeated intracerebral infusions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebral Dopamine Neurotrophic Factor
Description: Repeated intracerebral infusions
Study: NCT02100722

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CABG
Description: Coronary Artery Bypass Graft Surgery (CABG)
Study: NCT03295786

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cerebral Dopamine Neurotrophic Factor
Description: Repeated intracerebral infusions

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renishaw Drug Delivery System
Description: Stereotactically implanted device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Renishaw Drug Delivery System
Description: Stereotactically implanted device

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Renishaw Drug Delivery System
Description: Stereotactically implanted device
Study: NCT04007549

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief motivational interview on tobacco/alcohol risk reduction
Description: The intervention is a couple brief motivational interview (CBMI) on tobacco/alcohol risk reduction, delivered in a single session and a booster session one month later.~It is based on motivational interviewing principals (patient-centered communication, expression of empathy, develops discrepancy, deal with resistance to change, support self-efficacy and autonomy), with feedback on tobacco / alcohol consumption, information delivery and if needed referral to treatment. The intervention also specifically focuses on relational dynamics, and marital support development. This intervention will be compared with a single individual brief motivational intervention (IBMI) and a booster session one month later, only delivered to the patient; and the partner receive e-mail or postal brief advices.~All brief interventions will be carried out by the same psychologist trained and supervised for this type of intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief motivational interview on tobacco/alcohol risk reduction
Description: The intervention is a couple brief motivational interview (CBMI) on tobacco/alcohol risk reduction, delivered in a single session and a booster session one month later.~It is based on motivational interviewing principals (patient-centered communication, expression of empathy, develops discrepancy, deal with resistance to change, support self-efficacy and autonomy), with feedback on tobacco / alcohol consumption, information delivery and if needed referral to treatment. The intervention also specifically focuses on relational dynamics, and marital support development. This intervention will be compared with a single individual brief motivational intervention (IBMI) and a booster session one month later, only delivered to the patient; and the partner receive e-mail or postal brief advices.~All brief interventions will be carried out by the same psychologist trained and supervised for this type of intervention.
Study: NCT01259492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin LA 20 mg
Description: Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin LA 20 mg
Description: Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin LA 20 mg
Description: Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin LA 30 mg
Description: Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritalin LA 30 mg
Description: Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
Study: NCT03640091

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Post-extractive inter-radicular implant bed preparation
Description: Implant placement in mandibular molars
Study: NCT02270398

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dual-task training group
Description: Balance and gait exercises while simultaneously engaging in a secondary cognitive task.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single-task training group
Description: Balance/gait exercises and cognitive exercises done separately.
Study: NCT03564730

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous Knee Arthroplasty (UKA)
Description: Patient will have both knees completed under one anesthetic.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Simultaneous Knee Arthroplasty (UKA)
Description: Patient will have both knees completed under one anesthetic.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged Knee Arthroplasty (UKA)
Description: Patient will have knees completed under 2 anesthetics.
Study: NCT02100722

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Integrity Stent
Description: Durable polymer zotarolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resolute Onyx Stent
Description: Durable polymer zotarolimus-eluting stent
Study: NCT03054974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modern rehabilitation treatment
Description: PT 1 hour per day and OT 30min per day

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modern rehabilitation &TCM
Description: Traditional Chinese Medicine, including massage and medicated bath

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modern rehabilitation &Baimai Ruangao
Description: modern rehabilitation treatment with Baimai Ruangao and massage
Study: NCT02270398

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Flexibility and strength training group
Description: Whole-body flexibility exercises, upper limb strengthening exercises.
Study: NCT03664986

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Bupivacaine
Description: The objective of our study is to compare the use of EXPAREL in minimizing post-operative pain after sacrospinous ligament fixation with or without concomitant procedures for pelvic organ prolapse, with or without suburethral sling. We hypothesize that pudendal nerve blockage using long-acting EXPAREL will reduce post-operative pain and potentially reduce oral narcotic consumption. It may also reduce the incidence of postoperative constipation and patient satisfaction.
Study: NCT03564730

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Staged Knee Arthroplasty (UKA)
Description: Patient will have knees completed under 2 anesthetics.
Study: NCT03054974

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: modern rehabilitation &Tibetan medicine
Description: modern rehabilitation treatment and Tibetan medicine(medicated bath with wuweiganlu and rub with baimairuangao)
Study: NCT04343885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-PSMA-617
Description: Patients will be given 7.5GBq of 177Lu-PSMA every 6 weeks for 2 cycles.
Study: NCT03867084

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion of Pembrolizumab 200 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV infusion of 0.9% normal saline.
Study: NCT03071302

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EVALUATION OF VSX1, SOD1, and TIMP3 genes
Description: Evaluation of VISX1, SOD1, TIMP3 genes in corneal epithelium, and in peripheral blood. Evaluation of pentacam parameters
Study: NCT01237678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IMGN901
Description: Phase 2 regimen is IMGN901, Carboplatin, and Etoposide. IMGN901 to be given on days 1 and 8 every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin and Etoposide
Description: Patients assigned to Arm 2 were to receive carboplatin at the same AUC as utilized in Arm 1
Study: NCT03071302

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: EVALUATION OF VSX1, SOD1, and TIMP3 genes
Description: Evaluation of VISX1, SOD1, TIMP3 genes in corneal epithelium, and in peripheral blood. Evaluation of pentacam parameters
Study: NCT04343885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles

Intervention type: DRUG
Group type: OTHER
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles
Study: NCT01328288

Intervention type: DRUG
Intervention: standard ART according to the Thai Ministry of Public Health national guidelines
Description: Patients may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
Study: NCT02310958

Intervention type: PROCEDURE
Intervention: Laparoscopic surgical hernia repair
Description: Laparoscopic surgical hernia repair in children
Study: NCT03686254

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: RFA, bevacizumab and second-line chemotherapy
Description: Navigated by CT-ultrasound merged images, RFA is taken in the experimental arm at the first day of the first cycle during the second-line therapy. Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI \[Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 \[Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab and second-line chemotherapy
Description: Bevacizumab is given to patients in all arms every 2 weeks (5mg/kg) or 3 weeks (7.5mg/kg), intravenous drip(VD). The second-line chemotherapies include FOLFIRI \[Irinotecan 180 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or irinotecan monotherapy (125 mg/m2 D1, 8, q3W or 180 mg/m2 D1, q2W), mFOLFOX6 \[Oxaliplatin 85 mg/m2 D1+Calcium folinatc 400 mg/m2 or Calcium Levofolinate 200 mg/m2 D1+5-FU 400 mg/m2 D1, 2400 mg/m2 D1-2(46-48h), q2W\] or CapeOX (Oxaliplatin 130 mg/m2 D1+Capecitabine 1000 mg/m2 Bid D1-14, q3W)，or irinotecan+oxaliplatin (Oxaliplatin 85 mg/m2 D1+Irinotecan 200 mg/m2 D1, q3W). Among these strategies, the treatment cycle of FOLFIRI, irinotecan monotherapy and mFOLFOX6 is two weeks, while three weeks in CapeOX and irinotecan + oxaliplatin.
Study: NCT02989636

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study: NCT01020292

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Study: NCT04129060

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholinergic antagonist
Description: The cholinergic antagonist drug mecamylamine will be administered as a a 20 mg oral pill and matching placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cholinergic antagonist
Description: The cholinergic antagonist drug mecamylamine will be administered as a a 20 mg oral pill and matching placebo
Study: NCT02974062

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercise
Description: Participants were trained using lumbar stabilization exercise based on their initial lumbar stability level. They were received a 30-minute exercise for 1 session in this study.
Study: NCT01157871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XRP0038 (NV1FGF)
Description: Pharmaceutical form:solution~Route of administration: intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XRP0038 (NV1FGF)
Description: Pharmaceutical form:solution~Route of administration: intramuscular

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Pharmaceutical form:solution~Route of administration: intramuscular
Study: NCT02807909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177
Study: NCT01965093

Intervention type: PROCEDURE
Intervention: perioperative desaturation
Description: children aged 0-5 years old who receive general anesthesia and developed perioperative desaturation

Intervention type: PROCEDURE
Intervention: no perioperative desaturation
Description: children aged 0-5 years who did not developed perioperative desaturation under general anesthesia
Study: NCT00397254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rizatriptan
Description: 10mg ODT 27 tablets
Study: NCT02807909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986177

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diltiazem ER
Study: NCT00397254

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rizatriptan
Description: 10mg ODT 9 tablets
Study: NCT01217658

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Happiest Baby on The Block
Description: Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AAP Infant Colic counseling
Description: Those receiving the control group allocation will be counseled using the American Academy of Pediatrics material for Infant Colic.
Study: NCT02133638

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sevoflurane
Description: Induction of anesthesia: fentanyl 2 µg kg-1 and a bolus inhalation of 8% sevoflurane in an 8 L.min-1 fresh gas flow. Anesthesia maintenance: 1 minimal alveolar concentration (MAC) sevoflurane at a low fresh gas flow of 0.6-0.8 L min-1 in a 60% air-oxygen mixture supplemented with boluses of fentanyl.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Induction of anesthesia: propofol 2 mg kg-1 and fentanyl 4 µg kg-1. Maintenance of anesthesia: infusion of propofol 8 mg kg-1 h-1 and boluses of fentanyl 3 µg kg-1.
Study: NCT00005655

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rh IL-12
Description: rhIL-12 will be administered intravenously on days 2, 4, 6, 10, 12 and 14 of each cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rh IL-2
Description: rhIL-2 will be administered intravenously every 8 hours x 3 doses on days 1 and 9 of each cycle.
Study: NCT03236350

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active autoRIC® (CRIC Treatment)
Description: The active autoRIC® Device is programmed to go through a preset protocol of inflation and deflation cycles every session. The sessions will be repeated daily for 28 days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Control autoRIC® (Sham Control)
Description: The Sham Control autoRIC® Device is visually identical to the active autoRIC® Device but the simulated protocol applied comprises of vibrations of the device but no inflation of the cuff every session. The sham device provides the same sound and vibration as that of the pump inflating and the same LED indicators on the Active Unit. The sessions will be repeated daily for 28 days.
Study: NCT03934593

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Faith-Based (FB, BHT DSMS)
Description: BHT DSMS Intervention components include Health Sermon and a 6-session Health Bible Study with cooking demonstrations, followed by the Stanford DSMP and a Diabetes Resource Seminar. All intervention activities are implemented by trained church lay leaders.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Faith-Placed (FP, Stanford DSMP)
Description: Standard Stanford DSMP delivered by health professional
Study: NCT02096692

Intervention type: DEVICE
Intervention: Patients with a ProMRI ICD System
Description: Tachycardia Fast Heart Beat
Study: NCT02107391

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic Cells DCVAC/PCa
Description: Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide acetate
Description: Standard of Care Hormone Therapy as an Active Comparator

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Standard of Care Hormone Therapy as an Active Comparator
Study: NCT02238405

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensive anti-smoking counseling
Description: Study participants randomized to the intervention arm will receive intensive cessation support outside of the TB clinic setting, from a health worker trained in cessation counseling, during the course of their TB treatment. Behavioral elements will consist of follow up using unscheduled drop in or phone sessions, motivational interviewing, and counseling tailored to the needs and circumstances of the patient. Patients who are current smokers and are ready to commit to quit smoking will be supported to stop completely. Recent smokers will supported for having quit, and the counselor will discuss coping strategies to maintain abstinence.
Study: NCT02416687

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Implanon®
Description: Postpartum women into whom the etonogestrel-releasing contraceptive implant was inserted in the first 48 h postpartum
Study: NCT01629667

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tralokinumab
Description: Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
Study: NCT02096692

Intervention type: OTHER
Intervention: Magnetic Resonance Imaging (MRI) scan
Description: MRI scan of heart/chest or thoracic spine
Study: NCT01652638

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.
Study: NCT02587143

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ethyl chloride
Description: Nurses will administrate ethyl chloride vapocoolant spray on patient's skin a few seconds before arterial puncture (of cubital arteria).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alcohol
Description: Nurses will use an alcohol-based spray as placebo on patient's skin a few seconds before arterial puncture (of cubital arteria).
Study: NCT01629667

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
Study: NCT04098952

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: Manual Therapy
Description: The treatment techniques used will be: ischemic compression in the trigger point of the masseter and soft-tissue release technique over the temporal region.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group 2: Interferential massage plus Manual Therapy
Description: In addition to the treatment techniques applied to the other group, an electric massage will be performed with interferential currents at the level of the cervical region.
Study: NCT00668343

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: simvastatin
Description: 40 mg/ day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 80 mg /day
Study: NCT02137772

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Letermovir
Description: Letermovir 240 mg / 480 mg tablets, or 240 mg / 480 mg intravenous solution in 250 mL to be infused over 60 minutes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, or intravenous solution in 250 mL to be infused over 60 minutes.
Study: NCT02986958

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-visit patient-family agenda-setting checklist
Description: Pre-visit patient-family agenda-setting checklist

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual care
Description: routine primary care